Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim Young

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Journal of Clinical Epidemiology|December 26, 2008
Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapyJim Young, Tracy R Glass, Enos Bernasconi, et al.
Scandinavian Journal of Work, Environment & Health|June 12, 2014
Assessing work ability--a cross-sectional study of interrater agreement between disability claimants, treating physicians, and medical expertsSalome Dell-Kuster, Simon Lauper, Joerg Koehler, et al.
AIDS (London, England)|March 9, 2012
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavirJim Young, Juliane Schäfer, Christoph A Fux, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 7, 2020
Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?Nadine Kronfli, Jim Young, Shouao Wang, et al.
AIDS Care|January 6, 2017
High prevalence of physical inactivity among patients from the Swiss HIV Cohort StudyJuliane Schäfer, Jim Young, Alexandra Calmy, et al.
The International Journal on Drug Policy|March 9, 2023
The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national eliminationJim Young, Shouao Wang, Charlotte Lanièce Delaunay, et al.
The International Journal on Drug Policy|December 30, 2018
Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antiviralsRoy Nitulescu, Jim Young, Sahar Saeed, et al.
Antiviral Therapy|April 16, 2019
The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort StudyJim Young, Alexandra U Scherrer, Alexandra Calmy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2017
Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIVJim Young, Carmine Rossi, John Gill, et al.
BMJ (Clinical Research Ed.)|January 3, 2004
Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort studyJim Young, Sabina De Geest, Rebecca Spirig, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Journal of Clinical Epidemiology|December 26, 2008
Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapyJim Young, Tracy R Glass, Enos Bernasconi, et al.
Scandinavian Journal of Work, Environment & Health|June 12, 2014
Assessing work ability--a cross-sectional study of interrater agreement between disability claimants, treating physicians, and medical expertsSalome Dell-Kuster, Simon Lauper, Joerg Koehler, et al.
AIDS (London, England)|March 9, 2012
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavirJim Young, Juliane Schäfer, Christoph A Fux, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 7, 2020
Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?Nadine Kronfli, Jim Young, Shouao Wang, et al.
AIDS Care|January 6, 2017
High prevalence of physical inactivity among patients from the Swiss HIV Cohort StudyJuliane Schäfer, Jim Young, Alexandra Calmy, et al.
The International Journal on Drug Policy|March 9, 2023
The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national eliminationJim Young, Shouao Wang, Charlotte Lanièce Delaunay, et al.
The International Journal on Drug Policy|December 30, 2018
Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antiviralsRoy Nitulescu, Jim Young, Sahar Saeed, et al.
Antiviral Therapy|April 16, 2019
The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort StudyJim Young, Alexandra U Scherrer, Alexandra Calmy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2017
Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIVJim Young, Carmine Rossi, John Gill, et al.
BMJ (Clinical Research Ed.)|January 3, 2004
Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort studyJim Young, Sabina De Geest, Rebecca Spirig, et al.
Pageof 8